

WEST**End of Result Set**☐ **Generate Collection**

L4: Entry 1 of 1

File: JPAB

Oct 6, 1998

PUB-NO: JP410265359A
DOCUMENT-IDENTIFIER: JP 10265359 A
TITLE: PREVENTIVE FOR WRINKLE FORMATION

PUBN-DATE: October 6, 1998

INVENTOR-INFORMATION:

NAME

TSUJI, NAKO

MORIWAKI, SHIGERU

IMOKAWA, GENJI

SUZUKI, YASUTO

NISHIZAWA, YOSHINORI

ASSIGNEE-INFORMATION:

NAME

KAO CORP

COUNTRY

N/A

APPL-NO: JP09071698

APPL-DATE: March 25, 1997

INT-CL (IPC): A61K 7/48; A61K 7/00

ABSTRACT:

PROBLEM TO BE SOLVED: To obtain a preventive for wrinkle formation, capable of preventing and improving the occurrence of wrinkle caused by aging of skin by including a metal-dependent elastin decomposing inhibitor as an active ingredient.

SOLUTION: This medicine comprises a metal-dependent elastin decomposing inhibitor, especially a metal-dependent elastin decomposing inhibitor derived from a fibroblast of corium, such as a phosphonic acid derivative or a mercaptopropionamide derivative as an active ingredient. The medicine is further formulated with an ultraviolet absorber or an ultraviolet controller to preferably prepare a skin preparation for external use. The formulated amount of the metal-dependent elastin decomposing enzyme inhibitor in the case of preparing the skin preparation for external use is preferably 0.0001-5 wt.% based on the whole composition. The elastin decomposing enzyme includes one belonging to a serine protease and one belonging to a metal-dependent protease. An elastase inhibitor belonging to the metal protease has excellent controlling action on wrinkle formation.

COPYRIGHT: (C)1998, JPO

WEST**End of Result Set****Generate Collection**

L5: Entry 1 of 1

File: DWPI

Dec 8, 1998

DERWENT-ACC-NO: 1998-531686

DERWENT-WEEK: 199908

COPYRIGHT 2000 DERWENT INFORMATION LTD

TITLE: Preventives against skin ageing such as wrinkles, sags, loss of skin tension - contain phosphoric acid derivative or its salt, or mercapto:propionamide derivative or its salt

INVENTOR: IMOKAWA, G; MORIWAKI, S ; NISHIZAWA, Y ; SUZUKI, Y ; TSUJI, N

PATENT-ASSIGNEE:

ASSIGNEE
KAO CORPCODE
KAOS

PRIORITY-DATA:

1997JP-0071700

March 25, 1997

1997JP-0071698

March 25, 1997

1997JP-0071699

March 25, 1997

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
JP 10324611 A	December 8, 1998	N/A	006	A61K007/00
WO 9842308 A1	October 1, 1998	J	023	A61K007/48
JP 10265359 A	October 6, 1998	N/A	006	A61K007/48
JP 10265360 A	October 6, 1998	N/A	006	A61K007/48

DESIGNATED-STATES: US AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	APPL-DESCRIPTOR
JP10324611A	March 10, 1998	1998JP-0058038	N/A
WO 9842308A1	March 18, 1998	1998WO-JP01143	N/A
JP10265359A	March 25, 1997	1997JP-0071698	N/A
JP10265360A	March 25, 1997	1997JP-0071700	N/A

INT-CL (IPC): A61K 7/00; A61K 7/42; A61K 7/48

ABSTRACTED-PUB-NO: WO 9842308A

BASIC-ABSTRACT:

A preventive for skin aging contains phosphoric acid derivs represented by formula R1-(CH)P(=O)-NHCH(R2)CONHCH(R3)COOH (I) or its salts.

Alternatively, it contains a metal-dependent-type elastic-decomposition enzyme inhibitor contg mercapto-propionamide deriv or its salt as a major component.

In (I), R1-3 = H, hydrocarbon group which may be substituted, or sucrose residual group.

USE - The preventive is used for cosmetic preparations such as skin lotions, skin creams etc..

ADVANTAGE - The preventive prevents formation of wrinkles and sags and decreases of skin tension.

ABSTRACTED-PUB-NO: WO 9842308A

EQUIVALENT-ABSTRACTS:

CHOSEN-DRAWING: Dwg.0/0

DERWENT-CLASS: D21 E19

CPI-CODES: D08-B09A; E05-G04; E05-G05; E05-G06; E07-H; E10-C04;

WEST**Freeform Search**

Database: **US Patents Full-Text Database** ▲
 JPO Abstracts Database
 EPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins ▼

Term:

Display: Documents in Display Format: Starting with Number

Generate: ☐ Hit List ☒ Hit Count ☐ Image

Search

Clear

Help

Logout

Interrupt

Main Menu

Show S Numbers

Edit S Numbers

Preferences

Search History

Today's Date: 7/28/2000

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT,JPAB,EPAB,DWPI	\$mercaptopropionamide same hair	5	<u>L12</u>
USPT,JPAB,EPAB,DWPI	phosphonic same hair	21	<u>L11</u>
USPT,JPAB,EPAB,DWPI	phosphonic same (elastase or neutral endopeptidase)	8	<u>L10</u>
USPT,JPAB,EPAB,DWPI	phosphonic and (elastase or neutral endopeptidase)	75	<u>L9</u>
DWPI	phosphonic and (elastase or neutral endopeptidase)	2	<u>L8</u>
DWPI	WO-9842308-\$.did.	1	<u>L7</u>
DWPI	WO 9842308-\$.did.	0	<u>L6</u>
DWPI	JP-10265359-\$.did.	1	<u>L5</u>
USPT,JPAB,EPAB,DWPI	\$mercaptopropionamide and (elastase or neutral endopeptidase)	1	<u>L4</u>
USPT,JPAB,EPAB,DWPI	\$mercaptopropionamide and hair	7	<u>L3</u>
USPT,JPAB,EPAB,DWPI	\$mercaptopropionamide and hair	0	<u>L2</u>
USPT,JPAB,EPAB,DWPI	mercaptopropionamide and hair	0	<u>L1</u>

*****STN Columbus *****

FILE 'HOME' ENTERED AT 16:04:59 ON 28 JUL 2000

INDEX BIOSCIENCE

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS SINCE FILE
TOTAL

FULL ESTIMATED COST	ENTRY	SESSION
0.15		0.15

INDEX: ADISALERTS, ADISINSIGHT, AGRICOLA,
AIDSLINE, ANABSTR, AQUASCI,
BIOBUSINESS, BIOCOMMERCE, BIOSIS,
BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA,
CANCERLIT, CAPLUS, CEABA, GEN, CIN,
CONFSCI, CROPB, CROPL, DDFB, DDFU,
DGENE, DRUGB, DRUGLAUNCH,
DRUGMONOG2, ... ENTERED AT 16:05:06 ON 28 JUL
2000

56 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to
view
search error messages that display as 0* with SET DETAIL
OFF.

=> S (MERCAPTOPROPIONAMIDE OR
PHOSPHONICX)XELASTASE OR NEUTRAL
ENDOPROTEASE)

- 1 FILE BIOSIS
- 2 FILE BIOTECHNO
- 5 FILE CAPLUS
- 1 FILE CEABA
- 1 FILE DDFB
- 22 FILES SFARCHFD
- 3 FILE DDFU
- 1 FILE DRUGB
- 6 FILE DRUGU
- 1 FILE EMBASE
- 1 FILE EMBASE
- 1 FILE EMBASE
- 1 FILE EMBASE
- 1 FILE EMBASE
- 42 FILES SEARCHED...
- 2 FILE MFDIINE
- 1 FILE SCISEARCH
- 2 FILE TOXLIT

34 FILE USPATFULL

15 FILES HAVE ONE OR MORE ANSWERS, 56
FILES SEARCHED IN STNINDEX

L1 QUE (MERCAPTOPROPIONAMIDE OR
PHOSPHONICX)XELASTASE OR NEUTRAL
ENDOPROTEA
SE)

=> D RANK

- | F1 | 34 | USPATFULL |
|-----|----|-----------|
| F2 | 6 | DRUGU |
| F3 | 5 | CAPLUS |
| F4 | 3 | DDFU |
| F5 | 2 | BIOTECHNO |
| F6 | 2 | MEDLINE |
| F7 | 2 | TOXLIT |
| F8 | 1 | BIOSIS |
| F9 | 1 | CEABA |
| F10 | 1 | DDFB |
| F11 | 1 | DRUGB |
| F12 | 1 | EMBASE |
| F13 | 1 | ESBIOBASE |
| F14 | 1 | LIFESCI |
| F15 | 1 | SCISEARCH |

=> FILE F2-15

COST IN U.S. DOLLARS SINCE FILE
TOTAL

FULL ESTIMATED COST	ENTRY	SESSION
12.30		0.45

FILE 'DRUGU' ENTERED AT 16:08:16 ON 28 JUL 2000
COPYRIGHT (C) 2000 DERWENT INFORMATION LTD

FILE 'CAPLUS' ENTERED AT 16:08:16 ON 28 JUL 2000
USE IS SUBJECT TO THE TERMS OF YOUR STN
CUSTOMER AGREEMENT.
PIFASF SF "HELP USAGTERMS" FOR DETAILS.
COPYRIGHT (C) 2000 AMERICAN CHEMICAL
SOCIETY (ACS)

FILE 'DDFB' TEMPORARILY UNAVAILABLE

FILE 'BIOTECHNO' ENTERED AT 16:08:16 ON 28 JUL
2000

COPYRIGHT (C) 2000 Elsevier Science B.V., Amsterdam.
All rights reserved.

FILE 'MFDIINF' ENTERED AT 16:08:16 ON 28 JUL
2000

FILE 'TOXLIT' ENTERED AT 16:08:16 ON 28 JUL 2000

FILE 'BIOSIS' ENTERED AT 16:08:16 ON 28 JUL 2000
COPYRIGHT (C) 2000 BIOSIS(R)

FILE 'CEABA' ENTERED AT 16:08:16 ON 28 JUL 2000
COPYRIGHT (C) 2000 DECHEMA eV

FILE 'DDFB' TEMPORARILY UNAVAILABLE

FILE 'DRUGB' ENTERED AT 16:08:16 ON 28 JUL 2000
COPYRIGHT (C) 2000 DERWENT INFORMATION LTD

FILE 'EMBASE' ENTERED AT 16:08:16 ON 28 JUL 2000
COPYRIGHT (C) 2000 Elsevier Science B.V., All rights
reserved

FILE 'ESBIOBASE' ENTERED AT 16:08:16 ON 28 JUL
2000

COPYRIGHT (C) 2000 Elsevier Science B.V., Amsterdam.
All rights reserved.

FILE 'LIFESCI' ENTERED AT 16:08:16 ON 28 JUL 2000
COPYRIGHT (C) 2000 Cambridge Scientific Abstracts
(CSA)

FILE 'SCISEARCH' ENTERED AT 16:08:16 ON 28 JUL
2000

COPYRIGHT (C) 2000 Institute for Scientific Information
(ISI) (R)

If this message appears repeatedly, please notify the Help
Desk.

Enter "HELP STN" for information on contacting the nearest
STN Help

Desk by telephone or via SEND in the STNMAIL file.

=> S L1

L2 24 L1

=> DUP REM L2

PROCESSING COMPLETED FOR L2

L3 14 DUP REM L2 (10 DUPLICATES REMOVED)
ANSWERS 1-6 FROM FILE 'DRUGU'

ANSWERS '7-9' FROM FILE C.APLUS
ANSWERS '10' FROM FILE BIOTECHNO
ANSWERS '11-12' FROM FILE TOXITIT
ANSWERS '13' FROM FILE CHABA
ANSWERS '14' FROM FILE DRUGB

3 L3 AND PY 1998

3 FILES SEARCHED...
5 FILES SEARCHED...
6 FILES SEARCHED...
9 FILES SEARCHED...
14 9 L3 AND PY 1998

3 D BIB AB 1-9

L4 ANSWER 1 OF 9 DRUGU COPYRIGHT 2000
DERWENT INFORMATION LTD
AN 1995-15089 DRUGU C P B
TI Phosphorous acid analogs of L-680,833, a potent
monocyclic beta-lactam
inhibitor of human leukocyte elastase.
AU Durette P L; Chabin R M; Fletcher D S; Green B G;
Hanlon W A; Humes J L;
Knight W B; Lanza T J Jr; Mumford R A; Pacholok S;
MacCross M
CS Merck-U.S.A
LO Rahway, N.J., U.S.A
SO Bioorg. Med. Chem. Lett. (5, No. 3, 271-74, 1995) 1
Tab. 7 Ref.

CODEN: BMCL
AV Department of Medicinal Chemical Research, Merck
Research Laboratories,
PO Box 2000, Rahway, NJ 07065-0900, U.S.A.

LA English
DT Journal
FA AB; LA; CT
FS Literature
AB The synthesis and inhibitory activity against human
leukocyte

elastase (HLE) of several phosphorus acid
analogues of L-680833 (1)
are reported. The compounds and their corresponding
ethyl esters were
found to be potent and time-dependent inhibitors of HLE
in-vitro.

Cellular activity was demonstrated by inhibition of the
generation of the
N-terminal cleavage product A-alpha-(1-21) from the
A-alpha chain of

fibrinogen in whole blood stimulated with A-23187. The
compounds were,
however, only weakly active when dosed orally in the
hamster lung
hemorrhage assay

L4 ANSWER 2 OF 9 DRUGU COPYRIGHT 2000
DERWENT INFORMATION LTD
AN 1992-18583 DRUGU B
TI Substrate and Inhibitor Studies on Proteinase 3.
AU Kam C M; Kerrigan J F; Dolman K M; Goldschmieding
R; Borne A E G K von
dem; Powers J C

LO Atlanta, Georgia, United States; Amsterdam,
Netherlands
SO FEBS Lett. (297, No. 1-2, 119-123, 1992) 2 Fig. 2
Tab. 27 Ref.

CODEN: FEPLAL ISSN: 0014-5793
AV School of Chemistry and Biochemistry, Georgia
Institute of Technology,
Atlanta, GA 30332, U.S.A.

LA English
DT Journal
FA AB; LA; CT; MPC
FS Literature
AB Substituted isocoumarins (IC) were potent in-vitro
inhibitors of the
esterolytic activity of proteinase 3 (PR-3) extracted from
healthy human
blood neutrophils. The best inhibitor was 3,4-diCl-IC.
Peptide

phosphonates and peptide chloromethyl ketones were
poor inhibitors of
PR-3. Peptide thioesters were good substrates for PR-3.
A comparison of
the activities of PR-3 with those previously reported for
human
neutrophil elastase (HNE) indicated that there are
differences in the
extended substrate binding sites and the catalytic residues.
Thioester
substrates and IC inhibitors should be useful for further
studies on the
functional role of PR-3 in-vivo and in-vitro.

L4 ANSWER 3 OF 9 DRUGU COPYRIGHT 2000
DERWENT INFORMATION LTD
AN 1991-17340 DRUGU P B C
TI Irreversible Inhibition of Serine Proteases by Peptide
Derivatives of
(alpha-Aminoalkyl)phosphonate Diphenyl Esters.

AU Oleksyszyn J; Powers J C
LO Atlanta, Georgia, United States
SO Biochemistry (30, No. 2, 485-93, 1991) 2 Fig. 4 Tab.
32 Ref.
CODEN: BICHAW ISSN: 0006-2960
AV School of Chemistry, Georgia Institute of Technology,
Atlanta, Georgia
30332, U.S.A

LA English
DT Journal
FA AB; LA; CT; MPC
FS Literature
AB 20 Peptidyl (alpha-aminoalkyl)-phosphonate diphenyl
esters (APDE; see
formula sheet) with substrate-related sequences were
synthesized and
found to be specific irreversible inactivators of serine
proteases
including bovine chymotrypsin (BC), porcine pancreatic
elastase (PPE),
human leukocyte elastase (HLE), cathepsin G (CG) and
rat mast cell
protease II (MCP). The inhibitor-enzyme complexes
were extremely stable.
All the tri- and tetrapeptide phosphates (8-21) were more
potent
inhibitors than the simple benzyl oxy-carbonyl derivatives
(1-7). The
inhibitory potency was dependent on the amino acid
sequence of the
peptide. The APDE were chemically stable, stable in
plasma and did not
react with AChE.

L4 ANSWER 4 OF 9 DRUGU COPYRIGHT 2000
DERWENT INFORMATION LTD
AN 1989-14882 DRUGU P B
TI Molecular Drug Research: A Review of Mechanism
Directed Serine Protease
Inhibitors.

AU Demuth H U; Neumann U
LO Halle, Germany; East
SO Pharmazie (44, No. 1, 1-11, 1989) 5 Tab. 153 Ref.
CODEN: PHARAT ISSN: 0031-7144
AV Domplatz 1, Halle (Saale), DDR-4020.
LA German
DT Journal
FA AB; LA; CT
FS Literature
AB A review of the biospecific drug design of inhibitors of
serine

proteases, as exemplified by trypsin, chymotrypsin, plasmin and ***elastases***, is presented. A range of different types of inhibitor have been developed, including affinity labelling inhibitors, transition state inhibitors, acyl enzyme inhibitors (inverse substrates) and enzyme activated inhibitors (suicide substrates). Various classes of compound, which are represented by these inhibitor categories are discussed and methods for determination of the kinetics of enzyme inhibition are surveyed. Structure activity considerations allied to modern analytical methods (high resolution NMR, crystallography, computer graphics) have resulted in highly selective inhibitors, which may lead to new therapeutic and diagnostic agents.

I.4 ANSWER 5 OF 9 DRI'GT' COPYRIGHT 2000 DERWENT INFORMATION LTD
AN 1983-38312 DRUGU P B C
TI Aminoalkylphosphonofluoridate Derivatives: Rapid and Potentially Selective Inactivators of Serine Peptidases.
AU Larden L. A; Bartlett P. A
IO Berkeley, California, United States
SO Biochem Biophys Res Commun. (112, No. 3, 1085-90, 1983) 1 Tab. 16 Ref.
CODEN: BBRC A9 ISSN: 0006-291X
AU Dept. of Chemistry, University of California, Berkeley, California 94720, U.S.A.
LA English
DT Journal
FA AB; LA; CT; MPC
FS Literature
AB ***Phosphonic*** acid analogs of N-Cbz-alanine and N-Cbz-phenylalanine were converted to ester and amide fluorides. The compounds, 16 and 2, which mimic the natural peptide substrates, were the most potent inactivators of ***elastase*** and alpha chymotrypsin yet found

I.4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2000 ACS

AN 1996-599235 CAPLUS
DN 125:247628
TI 2-(2-Oxo-1,2-dihydro-1-pyridyl)-N-(3,3,3-trifluoro-1-(lower alkyl)-2-oxopropyl)acetamide derivatives as inhibitors of human leukocyte elastase
IN Bernstein, Peter R.; Shaw, Andrew; Thomas, Royston M.; Warner, Peter.
Wolarin, Donald J.
PA Zeneca Limited, UK
SO U.S., 70 pp. Cont.-in-part of U.S. Ser. No. 869,993, abandoned
CODEN: USXXAM
DT Patent
LA English
FAN CNT 3
PATENT NO. KIND DATE APPLICATION
NO. DATE
PI U.S. 5521179 A 19960528 U.S. 1993-45009
19930408 --
Z A 9302697 A 19931028 Z A 1993-2697
19930416 --
PRAI GB 1991-8357 19910418
GB 1991-8358 19910418
GB 1992-5392 19920312
GB 1992-8379 19920416
GB 1992-8380 19920416
U.S. 1992-869993 19920416
U.S. 1992-869993 19920416
GB 1992-1448 19920708
GB 1992-17362 19920814
GB 1992-17363 19920814
GB 1992-17364 19920814
OS MARPAT 125:247628
AB The present invention relates to certain novel heterocyclic amides which are 1-pyridylacetamide compds. I wherein: R0 is C1-5 alkyl; R = e.g., H, acyl, sulfonyl; R5 and R6 = e.g., H, lower alkyl, B-Y where B is aryl or heteroaryl and Y is a direct bond, methylene, ethylene, or trans-vinylene (with proviso), which are inhibitors of human leukocyte elastase (HLE), also known as human neutrophil elastase (HNE), making them useful whenever such inhibition is desired, such as for research tools in pharmacol., diagnostic and related studies and in the treatment of

diseases in mammals in which HLE is implicated. The Ki values for I which were tested are generally on the order of 10⁻⁷ M or much less. The invention also includes intermediates useful in the synthesis of these heterocyclic amides, processes for prepg. the heterocyclic amides, pharmaceutical compns. contg. such heterocyclic amides and methods for their use. Thus, e.g., acetophenone was formylated and cyclized with cyanoacetamide to provide 6-phenylpyrid-2-one-3-carbonitrile; hydrolysis to the carboxylic acid followed by urethane formation yielded 3-benzoyloxy-carbonylamino-6-phenylpyrid-2-one; alkylation of the latter with N-(2-tert-butylidimethylsilyloxy-3,3,3-trifluoro-1-isopropylpropyl)-2-iodoacetamide (prepn. given) followed by deprotection and oxidn. afforded 2-(3-benzoyloxy-carbonylamino-2-oxo-6-phenyl-1,2-dihydro-1-pyridyl)-N-(3,3,3-trifluoro-1-isopropyl-2-oxopropyl)acetamide (I; R = CH₃, R5 = H, R6 = Ph, R0 = iso-Pr).

L4 ANSWER 7 OF 9 BIOTECHNO COPYRIGHT 2000 Elsevier Science B.V.
AN 1993-23153203 BIOTECHNO
TI Patent selections
SO Current Opinion in Therapeutic Patents, (***1993***), 3 5 (667-673)
CODEN: COTPEP ISSN: 0962-2594
DT Journal; Note
CY United Kingdom
LA English
L4 ANSWER 8 OF 9 CEABA COPYRIGHT 2000 DECEMA
AN 1996-167810 CEABA
TI Catalytic reaction mechanism-based design of low-molecular inhibitors of proteolytic enzymes
Projektowanie niskocząsteczkowych inhibitorów enzymów proteolitycznych na podstawie znajomości mechanizmu katalizowanej reakcji
AU Kafarski, P.; Gancarz, R. (Wrocław, PL), 50:370

Wroclaw, Poland)
 SO Wiad. Chem. (***1996***) 50(1 2), p 53-76,
 18f,2l,33l
 CODEN: WICHAP ISSN: 0043-5104
 DT Journal
 LA Polish
 AB Practical aspects of designing the reaction
 mechanism-based inactivators
 of proteolytic cysteine, serine, aspartyl and
 metalloprotease enzymes
 were discussed. The chemistry of interactions between a
 variety of
 peptide inhibitors especially with ***phosphonic***,
 sulfonic,
 sulfoxide, ketone or aldehyde groups (leucopetidine,
 fluorophosphate,
 bestatine, zinc complexants) and papaine, cathepsin G,
 chymotrypsin,
 elastase, HIV virus protease, carboxypeptidase A
 or thermolysine
 enzymes as a base for drug designing was outlined. For
 instance, the
 inhibition of renine and angiotensin-converting enzyme
 with BPP5
 oligopeptide from Bothrops jararaca lizard venom gave
 an assumption for
 designing commercial captopril und cilazapril
 antihypertensives. Paper
 was given at the 5th Symposium on Peptide
 Conformation and Protein
 Structure, Karpacz, Poland, 29 April to 2 May 1995.
 (Polaczek)

L4 ANSWER 9 OF 9 DRUGB COPYRIGHT 2000
 DERWENT INFORMATION LTD
 AN 1978-41233 DRUGB B
 TI ORGANOPHOSPHORUS COMPOUNDS AS
 ACTIVE SITE-DIRECTED INHIBITORS OF
 ELASTASE.
 AU NAYAK P L, BENDER M L
 LO EVANSTON, ILL., USA
 SO BIOCHEM. BIOPHYS. RES. COMMUN. (83, NO. 3,
 1178-82, ***1978***)
 DT Journal

INDEX BIOSCIENCE

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
 COST IN U.S. DOLLARS
 SINCE FILE
 TOTAL

COST IN U.S. DOLLARS
 TOTAL
 FULL ESTIMATED COST
 42.05
 DISCOUNT AMOUNTS (FOR QUALIFYING
 ACCOUNTS) SINCE FILE
 CA SUBSCRIBER PRICE
 -0.56
 SINCE FILE
 ENTRY SESSION
 3.60
 TOTAL
 ENTRY SESSION
 0.00

=> D RANK

F1 277 USPATFULL
 F2 29 CAPLUS
 F3 21 WPIDS
 F4 21 WINDEX
 F5 17 IFIPAT
 F6 8 TOXLIT
 F7 3 JICST-EPLUS
 F8 1 BIOSIS
 F9 1 CABA
 F10 1 DRUGB
 F11 1 EMBASE
 F12 1 MEDLINE
 F13 1 SCISEARCH
 F14 1 TOXLINE

=> S L5 AND (INHIBIT? OR DEPLAT? OR PREVENT?)

1 FILE BIOSIS
 12 FILES SEARCHED...
 1 FILE CABA
 9 FILE CAPLUS
 0* FILE DDFB
 0* FILE DDFU
 22 FILES SEARCHED...
 23 FILES SEARCHED...
 1 FILE EMBASE
 32 FILES SEARCHED...
 2 FILE IFIPAT
 39 FILES SEARCHED...
 1 FILE MEDLINE
 1 FILE SCISEARCH
 1 FILE TOXLINE
 52 FILES SEARCHED...
 1 FILE TOXLIT
 205 FILE USPATFULL
 1 FILE WPIDS

ENTRY SESSION
 26.15
 FULL ESTIMATED COST
 38.45
 DISCOUNT AMOUNTS (FOR QUALIFYING
 ACCOUNTS) SINCE FILE
 CA SUBSCRIBER PRICE
 -0.56
 SINCE FILE
 ENTRY SESSION
 -0.56
 TOTAL
 ENTRY SESSION

INDEX 'ADISALERTS, ADISINSIGHT, AGRICOLA,
 AIDSLINE, ANABSTR, AQUASCI,
 BIOBUSINESS, BIOCOMMERCE, BIOSIS,
 BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA,
 CANCERLIT, CAPLUS, CEABA, CEN, CIN,
 CONFSCI, CROPB, CROPU, DDFB, DDFU,
 DGENE, DRUGB, DRUGLAUNCH,
 DRUGMONOG2, ...' ENTERED AT 16:11:26 ON 28 JUL
 2000

56 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to
 view
 search error messages that display as 0* with SET DETAIL
 OFF.

S (MERCAPTOPROPION-AMIDE OR
 PHOSPHONIC/L)(HAIR)

1 FILE BIOSIS
 1 FILE CABA
 24 FILES SEARCHED...
 1 FILE DRUGB
 1 FILE EMBASE
 17 FILE IFIPAT
 3 FILE JICST-EPLUS
 1 FILE MEDLINE
 50 FILES SEARCHED...
 1 FILE SCISEARCH
 1 FILE TOXLINE
 8 FILE TOXLIT
 277 FILE USPATFULL
 21 FILE WPIDS
 21 FILE WINDEX

14 FILES HAVE ONE OR MORE ANSWERS, 56
 FILES SEARCHED IN STNINDEX

L5 QUE (MERCAPTOPROPION-AMIDE OR
 PHOSPHONIC/L)(HAIR)

55 FILES SEARCHED
1 FILE WPINDEX

12 FILES HAVE ONE OR MORE ANSWERS, 56
FILES SEARCHED IN STINDEX

L6 QUE L5 AND (INHIBIT⁹ OR DEPI¹¹ AT⁹ OR
PREVENT⁷)

=> DRANK

F1 205 USPATFULL
F2 9 CAPLUS
F3 2 IFIPAT
F4 1 BIOSIS
F5 1 CABA
F6 1 EMBASE
F7 1 MEDLINE
F8 1 SCISEARCH
F9 1 TONLINE
F10 1 TOXLIT
F11 1 WPIDS
F12 1 WPINDEX

=> FILE F2-12

COST IN U.S. DOLLARS SINCE FILE
TOTAL

FULL ESTIMATED COST ENTRY SESSION
48.35 9.90

DISCOUNT AMOUNTS (FOR QUALIFYING
ACCOUNTS) SINCE FILE TOTAL

CASUBSCRIBER PRICE ENTRY SESSION
-0.56 0.00

FILE 'CAPLUS' ENTERED AT 16:25:43 ON 28 JUL 2000
USE IS SUBJECT TO THE TERMS OF YOUR STN
CUSTOMER AGREEMENT.
PLEASE SEE "HFIPUSAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2000 AMERICAN CHEMICAL
SOCIETY (ACS)

FILE 'IFIPAT' ENTERED AT 16:25:43 ON 28 JUL 2000
COPYRIGHT (C) 2000 IFI CLAIMS(R) Patent Services
(IFI)

FILE 'BIOSIS' ENTERED AT 16:25:43 ON 28 JUL 2000

COPYRIGHT (C) 2000 BIOSIS(R)

FILE 'CABA' ENTERED AT 16:25:43 ON 28 JUL 2000
COPYRIGHT (C) 2000 CAB INTERNATIONAL (CABI)

FILE 'EMBASE' ENTERED AT 16:25:43 ON 28 JUL 2000
COPYRIGHT (C) 2000 Elsevier Science B.V. All rights
reserved.

FILE 'MEDLINE' ENTERED AT 16:25:43 ON 28 JUL
2000

FILE 'SCISEARCH' ENTERED AT 16:25:43 ON 28 JUL
2000

COPYRIGHT (C) 2000 Institute for Scientific Information
(ISI) (R)

FILE 'TOXLINE' ENTERED AT 16:25:43 ON 28 JUL
2000

FILE 'TOXLIT' ENTERED AT 16:25:43 ON 28 JUL 2000

FILE 'WPIDS' ENTERED AT 16:25:43 ON 28 JUL 2000
COPYRIGHT (C) 2000 DERWENT INFORMATION LTD

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> S L6

7 FILES SEARCHED...
L7 19 L6

=> DUP REM

ENTER L# LIST OR (END):L7

PROCESSING COMPLETED FOR L7
L8 12 DUP REM L7 (7 DUPLICATES REMOVED)

ANSWERS '1-9' FROM FILE CAPLUS
ANSWERS '10-11' FROM FILE IFIPAT
ANSWER '12' FROM FILE WPIDS

=> S L8 AND PY< 1998

3 FILES SEARCHED...
4 FILES SEARCHED...
6 FILES SEARCHED...
7 FILES SEARCHED...
8 FILES SEARCHED...
-----User Break----->

u

SEARCH ENDED BY USER

=> D BIB AB 1-12

LOG Y

COST IN U.S. DOLLARS SINCE FILE
TOTAL

FULL ESTIMATED COST ENTRY SESSION
110.15 61.80

DISCOUNT AMOUNTS (FOR QUALIFYING
ACCOUNTS) SINCE FILE TOTAL

CASUBSCRIBER PRICE ENTRY SESSION
-0.56 0.00

STN INTERNATIONAL LOGOFF AT 16:46:35 ON 28
JUL 2000